Homepage Top Section1

The partnership between Boehringer Ingelheim and Lupin will develop LNP3794 as a potential targeted therapy for patients with difficult-to-treat cancers. The companies will develop the MEK inhibitor compound

The Maryland-based Insilico Medicine claimed that GENTRL can fast track the drug discovery process from years to days. The company is said to have validated the AI technology

The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral

Fasenra, which was developed by AstraZeneca’s MedImmune, was in-licensed from BioWa, a subsidiary of Japan-based Kyowa Hakko Kirin. Prior to receiving the orphan drug designation for eosinophilic oesophagitis,

The deal signed last month by the US-based Gilead Sciences and Galapagos has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 by the US Federal Trade

Oncorus, which is headquartered in Cambridge, Massachusetts, is an oncolytic virus company. It is engaged in advancing a portfolio of locally and systemically administered (IV) OV therapies based

The Dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) study demonstrated Farxiga’s potential with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the declining of heart

At present, the mRNA-1893 vaccine is being assessed in a phase 1 study to prevent Zika virus infection in healthy adults. The mRNA-1893 included an mRNA sequence that

Inrebic is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a